May Guo About mRNA Based in Vivo MG1113 Antibody Production as a Potential Therapeutic Approach for Hemophilia
May Guo, Vice President of Business Development at Biomay AG and Founder and CEO of Novaribo Consulting, shared a post on her LinkedIn account:
“mRNA/LNP encoding MG1113, a humanized monoclonal antibody that targets tissue factor pathway inhibitor (TFPI), to treat hemophilia. This paper shows that a single IV dose of mRNA-LNP achieves substantially higher peak serum concentrations of MG1113 antibody compared with direct antibody administration, demonstrating the pharmacokinetic advantage of mRNA-encoded antibody delivery.”
Title: mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia
Authors: Miyoung Oh, Yujeong Jeong, Hyein Jung, Yongjoo Byeon, Heechun Kwak, Songseop Kim, Wonhyo Seo, Jaesung Jung, Hyukjin Lee
Find more posts on Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas LangÖ‰ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge